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Abstract
Background Managed entry agreements (MEAs) are a set
of instruments to facilitate access to new medicines. This
study surveyed the implementation of MEAs in Central and
Eastern Europe (CEE) where limited comparative infor-
mation is currently available.
Method We conducted a survey on the implementation of
MEAs in CEE between January and March 2017.
Results Sixteen countries participated in this study. Across five
countries with available data on the number of different MEA
instruments implemented, the most common MEAs imple-
mented were confidential discounts (n = 495, 73%), followed
by paybacks (n = 92, 14%), price-volume agreements
(n = 37, 5%), free doses (n = 25, 4%), bundle and other
agreements (n = 19, 3%), and payment by result (n = 10,
[1%). Across seven countries with data on MEAs by thera-
peutic group, the highest number of brand names associated
with one or more MEA instruments belonged to the Anatomical
Therapeutic Chemical (ATC)-L group, antineoplastic and
immunomodulating agents (n = 201, 31%). The second most
frequent therapeutic group for MEA implementation was ATC-
A, alimentary tract and metabolism (n = 87, 13%), followed
by medicines for neurological conditions (n = 83, 13%).
Conclusions Experience in implementing MEAs varied
substantially across the region and there is considerable
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scope for greater transparency, sharing experiences and
mutual learning. European citizens, authorities and indus-
try should ask themselves whether, within publicly funded
health systems, confidential discounts can still be tolerated,
particularly when it is not clear which country and party
they are really benefiting. Furthermore, if MEAs are to
improve access, countries should establish clear objectives
for their implementation and a monitoring framework to
measure their performance, as well as the burden of
implementation.
Key Points for Decision Makers
Budget impact was the main concern behind
implementation of managed entry agreements
(MEAs) among Central and Eastern European (CEE)
countries, and most agreements implemented were
financial ones.
A high number of MEAs were implemented for
oncology and diabetes medicines.
European citizens, authorities and industry should
ask themselves whether, within publicly funded
health systems, confidential discounts can still be
tolerated.
1 Introduction
Managed entry agreements (MEAs) are a set of instruments
to facilitate access to new medicines, which are now rel-
atively well-established in a number of OECD (Organiza-
tion for Economic Cooperation and Development)
countries. Their use has increased over time [1] in response
to high prices for new medicines, particularly those for
cancer and orphan diseases [2, 3]; the need for payers to
work within finite budget limits; uncertainty regarding the
effectiveness of new medicines in routine clinical care
(real-life); and the willingness to address unmet need.
Different names are used to define MEAs as a group in
different countries, and there are different types of MEAs.
Despite their diversity, all these agreements have a com-
mon objective—to facilitate access to new medicines in a
context of uncertainty (around effectiveness and/or use in
real-life) and high prices [1]. The different names used in
different countries relate to the objectives they are trying to
achieve (e.g. patient access schemes in the UK), the nature
of the agreements (e.g. conventions in Belgium), and the
type of agreement (e.g. special pricing arrangements in
Australia) for example.
A variety of MEAs have been implemented worldwide.
Authors have tried to classify them in different ways,
notably dividing them into financial and health outcome-
Tanja Novakovic
tanjabel@hotmail.com
Guenka Petrova
guenka.petrova@gmail.com
Maciej Pomorski
m.pomorski@aotm.gov.pl
Dominik Tomek
tdmia@slovanet.sk
Luka Voncina
Lvoncina@gmail.com
Alan Haycox
a.r.haycox@liverpool.ac.uk
Panos Kanavos
p.g.kanavos@lse.ac.uk
Patricia Vella Bonanno
patricia.vella-bonanno@strath.ac.uk
1 LSE Health, London School of Economics and Political
Science, London, UK
2 Department of Pharmacy, Ministry of Health, Faculty of
Pharmacy, Riga Stradins University, Riga, Latvia
3 Department of Drug Management, Faculty of Health
Sciences, Jagiellonian University Medical College, 31-531
Krako´w, Poland
4 Society for Pharmacoecnomics and Outcomes Research in
Bosnia and Herzegovina, Sarajevo, Bosnia and Herzegovina
5 Corvinus University of Budapest, Budapest, Hungary
6 Department of Organization and Economy of Pharmacy,
Faculty of Pharmacy, Medical University-Sofia, 2-Dunav, str
Sofia 1000, Sofia, Bulgaria
7 Health Insurance Institute of Slovenia, Miklosˇicˇeva 24, 1507
Ljubljana, Slovenia
8 Department of Pharmacy, Ministry of Health of the Republic
of Lithuania, Vilnius, Lithuania
9 Department of Pharmacy, Faculty of Medicine, University of
Medicine Tirana, Tirana, Albania
10 Independent Consultant, Pristina, Kosovo
11 Head of Insurance Benefit Package, Estonian Health
Insurance Fund, Tallinn, Estonia
12 School of Public Policy, Central European University, Nador
u. 9, Budapest 1051, Hungary
13 Public Health and Management Department, Faculty of
Medicine, ‘‘Carol Davila’’ University of Medicine and
Pharmacy, Bucharest, 1-3, Dr. Leonte Anastasievici st.,
050463 Bucharest, Romania
14 Ministry of Health and Social Welfare, Banja Luka,
Republic of Srpska, Bosnia and Herzegovina
15 Department of Social Pharmacy, Medical Faculty, University
Banja Luka, Mrkalja 18, Banja Luka, Republic of Srpska,
Bosnia and Herzegovina
A. Ferrario et al.
based agreements [4, 5]. The latter are also called perfor-
mance-based agreements, although one could argue that
most of the financial agreements (apart from simple dis-
counts, for example) have a performance component (e.g.
payback for overspending, or coverage of a defined num-
ber of doses after which the manufacturer takes over the
cost). Financial agreements include discounts, price-vol-
ume agreements, payback agreement, free doses or dose-
capping schemes [4, 5]. Health outcome-based agreements
include different types of performance agreements
whereby reimbursement is linked to the performance of the
medicine in real-life or evidence development [4–6]. These
MEAs have also been called performance-based risk-
sharing arrangements (PBRSAs) [7, 8].
There is now a solid body of literature on the use,
advantages and disadvantages of MEAs as implemented in
Western Europe, North America and Australia
[1, 4–15, 17]; however, less information is available on
their impact [18–22]. Evidence on the use of MEAs in
Central and Eastern Europe (CEE), where these agree-
ments are increasingly being implemented, is much more
limited [23-25]. This is a concern as resources are more
constrained in these countries, as seen, for example, by
limited utilisation of biological medicines for rheumatoid
arthritis and bowel diseases compared with Western
European countries [26, 27]. Consequently, there is a need
to address this information gap to provide future direction.
To address this, we surveyed the implementation of
MEAs in CEE among senior payers, their advisers and
other senior stakeholders in these countries. In particular,
we investigated the rationale for introducing MEAs in
these countries, the types of agreement implemented, their
therapeutic focus, what happens once these agreements
come to an end, and other approaches to better manage the
entry of new medicines. In addition, we reviewed what
countries define as ‘risk’, ‘risk sharing’ and ‘high prices’.
The findings were used to highlight challenges and suggest
potential ways forward to improve access to new medicines
in the CEE region and beyond.
2 Methods
We conducted a survey on the implementation of risk
sharing and MEAs in CEE1 between January and March
2017. We developed a questionnaire (see electronic sup-
plementary material) that we sent to key informants in the
region. Key informants are co-authors (DA, TB, TC, DD,
MD, JF, KG, IGK, IH, AJ, EL, OL, IM, VM-P, DM, TN,
GP, MP, DT, LV) of this study and included senior staff in
competent authorities for pricing and reimbursement, aca-
demics with expertise on national pharmaceutical issues
and other national experts in pharmaceutical matters (e.g.
head of country International Society for Pharmacoeco-
nomics and Outcomes Research [ISPOR] chapters). Most
key informants were identified through the Piperska group
[25, 28, 29]—a multidisciplinary network of professionals
with interest in the quality use of medicines—either
through its membership or extended network.
The information collected was of both a qualitative and
quantitative nature. Qualitative questions included whether
MEAs are implemented, the rationale for implementing
them and what happens when an agreement comes to an
end. Quantitative information focused on the number of
agreements implemented, by type and Anatomical Thera-
peutic Chemical (ATC) group. The information provided
by the key informants in each country was based on their
knowledge of the national context, including where to find
information on MEAs available online (which may not be
simple to find due to language barriers, familiarity with the
national authority’s websites), access to non-published
information and a review of legislation relevant to MEAs.
An intensive data-cleaning process was subsequently
undertaken to harmonise the taxonomy used to classify
MEAs in different countries. This was done in collabora-
tion with the country experts to ensure the correct classi-
fication of the agreements according to a common
taxonomy. The taxonomy used was based on previous lit-
erature [4, 5], with minor adaptation to reflect the nature of
16 National Research Institution for Public Health, Moscow,
Russia
17 The Pharmacoeconomics Section, Pharmaceutical
Association of Serbia, Belgrade, Serbia
18 Department of Social Pharmacy and Pharmacoeconomics,
Faculty of Pharmacy, Medical University of Sofia, Sofia,
Bulgaria
19 Agency for Health Technology Assessment and Tariff
System (AOTMiT), Krasickiego Street, Warsaw, Poland
20 Faculty of Medicine, Slovak Medical University in
Bratislava, Bratislava, Slovakia
21 Independent Consultant, Zargreb, Croatia
22 Health Economics Centre, University of Liverpool
Management School, Liverpool, UK
23 Strathclyde Institute of Pharmacy and Biomedical Sciences,
University of Strathclyde, Glasgow G4 0RE, United
Kingdom
24 Division of Clinical Pharmacology, Karolinska Institute,
Karolinska University Hospital Huddinge, 141 86 Stockholm,
Sweden
1 In January 2017, the United Nations (UN) has changed the status of
Baltic states (Estonia, Latvia and Lithuania) from Eastern Europe to
Northern Europe. In this study, we consider them as part of CEE
countries.
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some agreements that would not have necessarily fitted into
previously proposed taxonomies.
2.1 Definition of Managed Entry Agreements
(MEAs) Used in this Study
In this study, we define MEAs as agreements made
between payers and pharmaceutical companies to manage
the impact of uncertainty around cost effectiveness and
volume, and the impact of high prices on access [15, 16].
Uncertainties around the value of new medicines, high
prices and the level of uptake of the new medicine can all
influence budget impact and cost effectiveness, and are
therefore key variables informing reimbursement decision
[1].
2.2 Counting MEAs
There are different options for enumerating MEAs. For
example, one can count:
1. The number of international non-proprietary names
(INNs) associated with one or more MEA instruments.
2. The number of different trade names associated with
one or more MEA instruments. This should, in
principle, be similar to option 1, apart from different
formulations of the same INN and ATC-5 group with
different trade names, e.g. Xeplion (1-month injection)
and Trevicta (3-monthly injection), same INN
(paliperidone) and ATC-5 group (N05AX13), both
marketed by Janssen-Cilag, which are counted sepa-
rately under option 2.
3. The number of different medicine indications associ-
ated with one or more MEA instruments (one INN may
have different MEAs for different indications).
4. The number of different MEA instruments imple-
mented (e.g. one INN/trade name may be associated
with different types of MEAs, such as a discount and a
payback, and these are counted separately under option
4).
5. The number of different agreements signed.
In this study, we enumerated the types of MEAs
implemented based on the number of different MEA
instruments implemented (option 4), and the number of
MEAs implemented in different therapeutic areas based on
the number of different trade names associated with one or
more MEA instruments (option 2). The choice of enu-
meration method was determined by data availability. Only
these two options were available across all countries that
submitted data on the number of agreements implemented,
either by type, therapeutic group or both. We consequently
used this approach.
3 Results
Sixteen CEE countries participated in this study by pro-
viding qualitative (16 countries) and quantitative infor-
mation on the types and numbers of MEAs implemented
(provided by eight countries; in four countries the number
of MEAs and the medicines involved are confidential or
was incomplete, three did not implement MEAs, and one
country was currently discussing the legislation, which
would enable their introduction at the time the survey was
conducted).
3.1 Use of MEAs
Most countries included in this study (n = 12) implemented
MEAs as defined in this study (Fig. 1). Three countries,
Albania, Kosovo and Russia, did not implement any
MEAs. One country, Slovakia, is currently discussing the
relevant legislation for implementing MEAs but, as of
February 2017, no official MEAs were in place. The aim of
the Ministry of Health in Slovakia is to increase access to
innovative medicines by introducing changes in the pricing
and reimbursement legislation, which would make it more
flexible. Some of the proposals currently being discussed
include the introduction of risk-sharing agreements, the
negotiation of confidential price agreements (whose use is
currently limited), higher willingness-to-pay thresholds,
and additional criteria for including new medicines in the
reimbursement list, including adopting a more societal
perspective in health technology assessment.
3.2 Rationale for Introducing MEAs
Countries cited different reasons for implementing MEAs.
These can be summarised in three main groups: working
within finite resources (n = 10), enabling access (n = 6)
and dealing with uncertainty around cost effectiveness and
use in real-life (n = 6) (Table 1). In most countries, MEAs
are enshrined in the legislation. Exceptions include Esto-
nia, where MEAs can be made as a result of price nego-
tiations with the manufacturer, and Bosnia and
Herzegovina, where, although not formally identified as
MEAs, special financial agreements with manufacturers of
on-patent medicines can be made to accelerate access for
limited number of patients or specific patient groups.
3.3 Types of MEAs Implemented
All countries with MEAs in place (n = 12) implemented
different types of financial agreements. Eight countries
(Bulgaria, Croatia, Czech Republic, Estonia, Hungary,
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Latvia, Poland and Romania) allowed for the implemen-
tation of health outcome-based MEAs (Table 2).
Across the five countries with available data on the
number of different MEA instruments implemented by type
(Slovenia, Hungary, Latvia, Estonia and Romania), the most
common MEAs implemented were confidential discounts
(n = 495, 73%), followed by payback (n = 92, 14%), price-
volume agreements (n = 37, 5%), free doses (n = 25, 4%),
bundle and other agreements (n = 19, 3%), and payment by
result (n = 10, 1%) (Fig. 2a). Although the implementation
of health outcome-based agreements is allowed in Estonia,
Hungary, Latvia and Romania, most of the agreements
implemented were financial (n = 668, 99% financial vs.
n = 10,[1% health outcome-based agreements). While no
data on the actual number of different MEA instruments
implemented were available in the other countries, survey
respondents reported that most agreements in Bulgaria,
Croatia, the Czech Republic, Poland, and Bosnia and
Herzegovina (including both The Federation of Bosnia and
Herzegovina, and the Republic of Srpska) were known to be
financial ones. No country with available data on the type of
MEAs implemented reported implementing coverage with
evidence development. In the Czech Republic, a large
number of innovative high-cost medicines have a special
status of ‘highly innovative medicinal products’ (vysoce
inovativnı´ le´cˇivy´ prˇı´pravek [VILP]) and, as such, are subject
to coverage with evidence development. They can be reim-
bursed for a maximum of 3 years, although exceptional cases
with temporary reimbursement beyond 3 years are also
known. Manufacturers are required to set up monitoring
systems, submit cost-effectiveness analysis, limit budget
impact and pay for treatment of existing patients after the end
of temporary reimbursement. As of March 2017, there were
19 VILPs (corresponding to six trade names) with temporary
Fig. 1 Implementation of
MEAs in Central and Eastern
Europe as of February 2017.
Countries coloured in blue
implement MEAs. The years
refer to the year the first MEA
was introduced in a particular
country. In some countries, for
example Serbia, the legislation
was introduced well before
(2014) the first MEA was signed
(2016). Countries coloured in
orange did not implement
MEAs as of February 2017, and
countries coloured in grey were
either not part of the study or we
did not have any information on
them. AL Albania, BG Bulgaria,
BH Bosnia and Herzegovina,
CZ Czech Republic, EE Estonia,
LT Lithuania, LV Latvia, HR
Croatia, HU Hungary, KV
Kosovo, PL Poland, RO
Romania, RS Serbia, SL
Slovenia, SK Slovakia, MEAs
managed entry agreements
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Table 1 Rationale for implementing MEAs and policy basis in Central and Eastern European countries
Rationale Policy basis
Albania Not implemented NA
Bosnia and
Herzegovina
The Federation of Bosnia and Herzegovina
Facilitating access to new medicines by reducing their price
and budget impact
Republika Srpska
Facilitating access to new medicines while working within
finite budgets
The Federation of Bosnia and Herzegovina
There are special conditions for the financing of new patented
medicines. These fit under the MEA definition used in this
study but are not officially recognised as MEAs
Republika Srpska
(1) Decision of the Health Insurance Fund on the criteria for
inclusion of medicines in the list of reimbursed medicines
(2) Decision on the criteria for inclusion of medicines in the
‘List of cytotoxic, biological and related medicines’ in order
to increase access and control expenses
(3) For the entry of expensive medicines, the ‘List of
medicines with the specific mode of acquisition’
Bulgaria Limiting expenditure on medicines by reducing the price of
medicines reimbursed by the National Health Insurance
Fund (since 2015). Addressing uncertainties around the cost
effectiveness and value of the newly included INN (since
2016, in force 2017)
Law on Health Insurance Art. 45, paragraphs 10 and 19
Croatia Increasing access and controlling expenditure Bylaw of the Croatian Health Insurance Fund reimbursement
of medicines rules (criteria for inclusion of medicines in the
basic and supplementary list) [49]
Czech
Republic
Increasing access to new therapies while containing
expenditure
Law 48/1997 on statutory health insurance, as amended
notably in 2011. It does not contain specific provisions on
MEAs, but recognises that sustainability of health care
financing is an integral part of public interest in health care
The same law introduces provisions on coverage with
evidence development for ‘highly innovative medicinal
products’ (‘VILPs)
Estonia Various, examples include uncertainty about the cost
effectiveness of the medicine in Estonia
No formal policy framework for MEAs, they are the result of
price negotiations with the manufacturer
Hungary (1) Mitigation of budget impact
(2) Uncertainty about clinical value
(3) Confidential way to manage price
Law 198/2006, 26.§
Kosovo Not implemented NA
Latvia To mitigate the impact of high prices, uncertainties around
cost effectiveness, and added value
MEAs are intended in Regulation No. 899 of the Cabinet of
Ministers on Procedures for the reimbursement of
expenditures for the acquisition of medicinal products and
medicinal devices intended for outpatient medical treatment
Lithuania High prices, balancing National Health Insurance Fund
budget, patients‘ access to treatment, possibility to prove
clinical and cost effectiveness, and addressing unmet
medical need
Mandatory (legal act, Ministry of Health) for all new
medicines that will increase budget impact in respect of
current standard of care
Poland (1) Enabling the introduction of new and costly medicines into
the reimbursement system in a better-controlled way
(2) Increasing and improving patients’ access to medicines and
other products
(3) Enhancing financial sustainability of the reimbursement
system
(4) Increasing flexibility of shaping the pricing and
reimbursement policy
Act of 12 May 2011 on reimbursement of medicines, food
products for special dietary use and medical devices
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reimbursement and 22 (13 trade names) that have received
permanent reimbursement. Approximately nine VILPs (five
trade names) are currently without coverage. The conditions
for obtaining VILP status are mandated by law and are
determined by the regulator, rather than by a contract
between manufacturers and payers, and as such they do not fit
the MEA definition used in this study. However, in the past
few years, payers have insisted on including clauses on
future MEAs for new VILP medicines. Other high-cost
medicines without VILP status can also be subject of MEAs
in the Czech Republic, but information on their existence is
limited and details are confidential.
By type, Estonia was the country with the highest
number of MEA instruments implemented (n = 237), fol-
lowed by Slovenia (n = 234), Hungary (n = 159), Latvia
(n = 42), and Romania (n = 6). In Estonia, if the medicine
is not cost effective at the given price and/or the budget
impact is too high, confidential discounts are negotiated;
these totalled 230, hence the high number of agreements
(Fig. 2b). These discounts are only valid for use in general
pharmacies (outpatient) and not for inpatient use (hospital
pharmacies) in Estonia. In Slovenia, MEAs were intro-
duced in 2005 and are mandatory for all new medicines
included in the reimbursement list, which explains the high
number of MEAs in place in this country.
Discounts were the most common type of MEA imple-
mented in Estonia (230 out of 237 agreements imple-
mented in the country), Slovenia (181 out of 234
agreements implemented in the country), and Hungary (84
out of 159 agreements implemented in the retail sector
country followed by 72 payback agreements). There are
approximately 40 MEAs in the hospital sector in Hungary
embedded into supply contracts won in central tenders;
however, no information is publicly available on the type
of MEA implemented in the hospital sector. In Hungary,
some MEAs are also in place for products accessible based
on individual patient applications (name-the-patient pro-
gramme) but no information was available on type of
agreement and medicines involved. Price-volume agree-
ments were the most common MEA instrument used in
Latvia (29 of 34 agreements implemented).
3.4 Total Number of Trade Names with MEAs
Implemented by Therapeutic Area
Across the seven countries with available data on the
number of different MEA instruments implemented by
therapeutic area (Bulgaria, Estonia, Hungary, Lithuania,
Latvia, Serbia and Romania), the highest number of trade
names associated with one or more MEA instruments
Table 1 continued
Rationale Policy basis
Romania Financial sustainability and cost predictability Emergency Government Ordinance no. 69/2014 (‘Cost-
volume/cost-volume-results contracts represent mechanisms
that ensure financial sustainability and cost predictability in
healthcare’) and Ministry of Health and National Health
Insurance House Common Order no. 3/1/2015
Russia Not implemented The implementation of MEAs is not possible due to Federal
Law #44. According to this law, all public purchases shall be
performed on the basis of tenders and the winner shall be
determined based on the lowest price. Theoretically, the
situation is different in private hospitals but they consider
risk-sharing schemes too sophisticated compared with their
routine needs. There were a number of announcements about
implementation of ‘risk-sharing’ in the Moscow region in
2017–2019 (not clear whether it should be public or private
hospitals). The key idea was to just pay for recovered
patients with hepatitis C. The latest information as of
January 2017 was that the region was looking for funding to
implement such a programme
Serbia To facilitate/enable inclusion of new medicines in the
reimbursement list
Rule book on criteria for inclusion and exclusion medicines on
the positive list
Slovakia The possibility of introducing MEAs is currently being discussed as an instrument, together with other changes in the
reimbursement legislation, to improve access to new medicines
Slovenia To address issues, high prices and low/uncertain cost
effectiveness
Health insurance law
Bosnia and Herzegovina is comprised of two constitutional and legal entities, the Federation of Bosnia and Herzegovina and the Republic of
Srpska. Financing, management, organisation and provision of health care are the responsibilities of each entity
MEAs managed entry agreements, NA not applicable, INN international non-proprietary name, VILPs vysoce inovativnı´ le´cˇivy´ prˇı´pravek
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belonged to the ATC-L group (n = 201, 31%); these were
mostly for antineoplastic agents ATC-L01/02 (n = 103),
and only a minority for immunomodulating agents ATC-
L03/04 (n = 44)2. The second most frequent therapeutic
group for MEA implementation was alimentary tract and
metabolism, ATC-A (n = 87, 13%), most of which were
implemented for medicines used in the treatment of dia-
betes ATC-A10 (n = 523), followed by nervous system
ATC-N (n = 83, 13%), anti-infectives for systemic use
ATC-J (n = 61, 9%), cardiovascular system ATC-C
(n = 49, 7%), blood and blood-forming organs ATC-B
(n = 47, 7%), respiratory system ATC-R (n = 35, 5%),
sensory organs ATC-S (n = 23, 4%), genitourinary system
and sex hormones ATC-G (n = 20, 3%), systemic hor-
monal preparations, excluding sex hormones and insulin
ATC-H (n = 18, 3%), musculoskeletal system ATC-M
(n = 17, 3%), various ATC-V (n = 11, 2%), and antipar-
asitic products, insecticides and repellents ATC-P (n = 2,
0.003%) (Fig. 3).
When counted by the number of different brand names
associated with one or more MEA instruments, Bulgaria
(n = 367) was the country with the highest number of
Table 2 Types of MEAs implemented in Central and Eastern European countries
Financial Health outcome-based
agreements
Discounts Price-
volume
agreements
Free
doses
Payback Bundle
agreements and
other agreements
Payment
by result
Coverage with
evidence
development
Albania Not implemented
Bosnia and Herzegovina (applies to both The
Federation of Bosnia and Herzegovina and
Republika Srpska)
H H H
Bulgaria H H H Hb H
Croatia H H H H Hd H
Czech Republic H H H H a
Estonia H H H H H
Hungary H c H H H H
Kosovo
Latvia H H H
Lithuania H H
Poland H H H He H
Romania H H
Russia Not implemented
Serbia H H Hf
Slovakia Not yet implemented
Slovenia H H H H H
Ticks (H) mean that the particular type of agreement is implemented in the country, with the exception of Croatia, Poland and the Czech
Republic where, since the type and number of agreements implemented is confidential, it represents possible agreements according to the
legislation or reported agreements based on information from key informants. Not all may be necessarily implemented
MEAs managed entry agreements
a Coverage with evidence development is implemented in the Czech Republic, however these do not fit the definition of MEAs used in this study
as there is no agreement with industry. Information on coverage with evidence development is publicly available in the Czech Republic
b In Bulgaria, bundle agreements were classified as those agreements covering, for example, the companion diagnostic of a medicine with MEA
c In Hungary, relevant legislation uses the term ‘price-volume agreement’ (PVA) for managed entry agreements in general. However PVA’s in
the strict sense are not used in Hungary
d In Croatia, bundle agreements included agreements for different products of the same manufacturer and also agreements across a particular
therapeutic area involving different manufacturers
e Other types in Poland include setting other conditions of reimbursement, which enhance availability of health services guaranteed by the
compulsory health care insurance or diminish costs of these services
f Allowed by the legislation but not yet implemented in Serbia as of February 2017
2 For 54 ATC-L agreements, the therapeutic group was only known
at ATC-1 level, not ATC-2.
3 For 13 ATC-A agreements, the therapeutic group was only known
at ATC-1 level, not ATC-2.
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different trade names associated with at least one MEA
instrument, followed by Estonia (n = 236), Hungary
(n = 134, retail sector only), Lithuania (n = 82), Latvia
(n = 42), Serbia (n = 18), and Romania (n = 5)
(Table 3). In Bulgaria since 2015, MEAs are required for
all new medicines to be included in the reimbursement list
and for on-patent medicines already included in the reim-
bursement list before 2015 to maintain coverage.
3.5 Termination of MEAs
The average duration of MEAs in the CEE countries
included in this study is 2 years, ranging from 1 to 5 years,
before the agreement is subject to re-negotiation (Table 4).
In Latvia, the majority of agreements are open-ended. In
most countries, either the agreement is renewed or a dif-
ferent agreement is signed (e.g. Slovenia). If the agreement
is not renewed, the medicine may cease to be funded (e.g.
Bulgaria and Romania). In Romania, after an agreement
comes to an end and before a new one is negotiated, there
can be a gap of 1–3 months. During this time period, the
manufacturer takes over the cost of medicines for patients
who have already started the treatment.
3.6 Other Approaches to Managed Entry
MEAs are one set of instruments to improve access to new
medicines, but they are not the only ones. For example,
some countries allocate special funds to enable some
patients to access new medicines. In the Federation of
Bosnia and Herzegovina (one of the two constitutional and
legal entities of Bosnia and Herzegovina together with the
Republic of Srpska), for instance, there is a special Soli-
Fig. 2 Total number of different MEA instruments implemented in
Slovenia, Hungary, Latvia, Estonia and Romania in 2016. a Overall.
One trade name may be associated with one or more MEA
instruments, e.g. discount and payback, and these were counted
separately. b By country. If a trade name was associated with more
than one MEA instrument, e.g. discount and payback, these were
counted separately. Data for Hungary include the retail sector only.
MEA managed entry agreement
Fig. 3 Number of trade names with one or more MEAs, by
therapeutic groups in Bulgaria, Hungary, Lithuania, Latvia, Serbia,
Estonia and Romania in 2015/16. The number of MEAs reported is by
total number of trade names with one or more MEAs, while Fig. 2a, b
present the total number of different MEA instruments implemented.
The 230 discount agreements in the outpatient sector in Estonia were
not included in Fig. 2 due to lack of data on the ATC group. The
remaining agreements (n=6) with available ATC information in
Estonia were included. MEA managed entry agreement, ATC
Anatomical Therapeutic Chemical, ATC-A alimentary tract and
metabolism, ATC-B blood and blood-forming organs, ATC-C cardio-
vascular system, ATC-G genitourinary system and sex hormones,
ATC-H systemic hormonal preparations, excluding sex hormones and
insulin, ATC-J anti-infectives for systemic use, ATC-L antineoplastic
and immunomodulating agents, ATC-M musculoskeletal system,
ATC-N nervous system, ATC-P antiparasitic products, insecticides
and repellents, ATC-R respiratory system, ATC-S sensory organs,
ATC-V various. There are approximately 40 MEAs in the hospital
sector in Hungary, approximately 25 of which were for oncology
treatments (ATC-L01/02) and 15 were contracts for other therapeutic
areas. Data for Hungary, Latvia, Serbia, Estonia and Romania refer to
2016, while data for Bulgaria and Lithuania refer to 2015
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darity Fund for the financing of so-called expensive
medicines and services such as transplantation, oncology,
biological therapies and HIV therapy following approval
by a Committee (based on medical documentation and
available budget). The list of medicines that may be eli-
gible for reimbursement through the Solidarity Fund is
available online [30]. The main problem with this approach
are waiting lists to gain access to these medicines.
In the Republic of Srpska, Bosnia and Herzegovina, the
entry of new and expensive medicines is enabled through
two lists of medicines reimbursed by the health insurance
fund. These are the ‘List of medicines with the specific
mode of acquisition’ and the ‘List of cytotoxic, biological
and related medicines’; the latter came into effect in Jan-
uary 2016. The budget for these lists is planned annually
and is funded from the overall budget of the health insur-
ance fund. Medicines in these lists cover various thera-
peutic areas, including treatments for oncology,
haemophilia, hepatitis B and C, cystic fibrosis, and multiple
sclerosis. The lists specify the indication eligible for
reimbursement.
3.7 Risk and Risk Sharing
Although these agreements are sometimes called risk-
sharing agreements, only some of them have a true risk-
sharing component (notably, paybacks and payment for
performance). None of the countries included in this study
specified in their legislation on MEAs what constitutes risk
or risk-sharing, they only specify the types of agreements
that may be implemented. Implicitly of course, the risk
they are managing is the risk of overspending due to
higher-than-forecasted volumes (addressed, for example,
through paybacks) and paying high prices for medicines
with limited added value in real-life or just unaffordable
(addressed, for example, via payment for performance
agreements.
4 Discussion
The extent of information available on MEAs varied sub-
stantially across the study countries. In Poland and Croatia,
only the types of agreements allowed by the legislation are
known, and some information is available on the submis-
sions made but not on the approved agreements. In the
Czech Republic, information about the existence of an
agreement can, in principle, be extracted from the regula-
tor’s public pricing and reimbursement decision (and since
July 2017, also from a public sector contracts registry), but
all details are confidential. While the details of the agree-
ments (e.g. the level of discount) are in commercial con-
fidence, the number of agreements implemented by the
therapeutic group and type should be publicly available.
Table 3 Number of trade names associated with one or more MEAs by therapeutic group in Bulgaria, Estonia, Hungary, Lithuania, Latvia,
Serbia and Romania in 2015/16
Bulgaria Estonia Hungary Lithuania Latvia Serbia Romania Total
Antineoplastic and immunomodulating agents (ATC-L) 96 5 32 32 22 10 4 201
Alimentary tract and metabolism (ATC-A) 42 32 10 3 87
Nervous system (ATC-N) 51 18 9 5 83
Anti-infectives for systemic use (ATC-J) 35 1 8 6 7 3 1 61
Cardiovascular system (ATC-C) 36 7 5 1 49
Blood and blood-forming organs (ATC-B) 24 9 7 5 2 47
Respiratory system (ATC-R) 18 11 6 35
Sensory organs (ATC-S) 19 3 1 23
Genitourinary system and sex hormones (ATC-G) 13 7 20
Systemic hormonal preparations, excl. sex hormones and
insulins (ATC-H)
14 3 1 18
Musculoskeletal system (ATC-M) 10 5 2 17
Various (ATC-V) 7 2 1 1 11
Antiparasitic products, insecticides and repellents (ATC-P) 2 2
Unknown 230 230
Total 367 236 134 82 42 18 5
The number of MEAs reported is by total number of trade names with one or more MEAs. Data for Hungary cover the retail sector only. At
hospital level, MEAs are embedded into supply contracts. There are approximately 40 MEAs in the hospital sector in Hungary, approximately 25
of which were for oncology treatments (ATC-L01/02) and 15 were contracts for other therapeutic groups. Data for Hungary, Latvia, Serbia,
Estonia and Romania refer to 2016, while data for Bulgaria and Lithuania refer to 2015
MEAs managed entry agreements, ATC Anatomical Therapeutic Chemical
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The experience in the CEE region in implementing
MEAs was also very diverse. In Slovenia, MEAs have been
implemented since 2006, while in Bulgaria and Romania
they were introduced in 2015. They have not been (offi-
cially) implemented in Albania, Bosnia and Herzegovina
(not formally identified as MEAs, but MEA-like agree-
ments are in place), Kosovo, Russia and Slovakia (some
confidential discounts are in place) as of March 2017. The
types of agreements implemented were predominantly
financial, with only very few health outcome-based
agreements. A 2015–2016 study on MEAs in eight Euro-
pean countries and administrative areas showed that most
of the agreements implemented for oncology medicines
were financial [17]. Across all countries with data on the
number of MEAs by therapeutic group, there was a strong
focus on agreements for oncological and diabetes medici-
nes, in line with findings from previous studies [1, 5, 8].
This is perhaps not surprising given the number of new
oncology treatments launched (70 products for 20 uses
between 2011 and 2015 [28]) and in clinical development
(over 586 molecules in 2015, representing an increase of
63% over the past 10 years [31]) and their associated high
entry prices, which can increase over the patent lifetime
[2, 32, 33]. As for diabetes, the chronic nature of the dis-
ease, and the availability of effective generic alternatives,
call for ways to reduce the budget impact of funding new
patented medicines given concerns with their costs and side
effects [3, 34]. In most cases, agreements are re-negotiated
and funding for the medicine continues; however, there
were exceptions. In Bulgaria and Romania, having an
Table 4 Duration of MEAs and next steps
Duration Possibility of
renewal
Albania MEAs are not implemented NA
Bosnia and
Herzegovina
The Federation of Bosnia and Herzegovina
Not officially implemented as MEAs but discount arrangements are in place to facilitate access to new
medicines by reducing their price and budget impact. Contract duration unknown
Republika Srpska
Discount agreements are linked to the tender process and are mostly valid for 1 year
Yes
Bulgaria One-year validity with annual renegotiation of discounts. If no discount is provided anymore, funding for
the medicine stops
Yes
Croatia 3 years, after which they are renegotiated, MEAs have to be renewed. The alternative would be delisting
but this has not happened as of February 2017
Yes
Czech Republic MEAs between payers and manufacturers: unlimited with contractual notice terms, or for 3 years
Coverage with evidence development (for highly innovative medicinal products, VILPs): 24 months,
renewable for an additional 12 months, exceptionally renewable further if no alternative therapy exists.
VILPs then either switch to permanent reimbursement, or are not reimbursed. In this case manufacturers
are obliged to finance therapy for existing patients, unless they can receive alternative therapy
Yes
Estonia 1–2 years Yes
Hungary Retail sector: Contract duration can be 1–4 years by law; in practice, many schemes are for 2 years.
Hospital sector: For contract-based schemes, the usual duration is 12 months, with some 24-month
contracts
Yes
Kosovo MEAs are not implemented NA
Latvia An MEA is a prerequisite for reimbursement for medicines with high budget impact and it is an
agreement between the NHS and MAH. If the scheme comes to an end and no new agreement is
reached, the medicine is no longer funded. The majority of these agreements are open-ended contracts
Yes
Lithuania A minimum of 3 years
Poland Between 2 and 5 years before reassessment Yes
Romania 1 year, after which they may be renegotiated. To date, it seems that only one product was not renegotiated
after the agreement came to an end
Yes
Russia MEAs are not implemented NA
Serbia 3 years Yes
Slovakia Not yet implemented NA
Slovenia Initially 3 years. If the agreement is not prolonged, the medicine is included in the portfolio discount or
another type of agreement
Yes
MEAs managed entry agreements, NA not applicable, VILPs vysoce inovativnı´ le´cˇivy´ prˇı´pravek, NHS National Health Service, MAH marketing
authorisation holder
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agreement in place is essential for reimbursement to be
maintained. Consequently, if re-negotiations are not suc-
cessful, funding for these medicines will be phased out.
Parallel trade can threaten medicines availability, which
is an issue in various CEE countries. Simple direct dis-
counts off the list price could make medicines attractive
targets for parallel trade because these medicines could be
sold in other countries at higher prices. Implementation of
health outcome-based agreements, paybacks or price-vol-
ume agreements are less likely to make medicines more
attractive targets for parallel trade (in comparison with
medicines without an MEA) unless the list price is sig-
nificantly lower than in other European countries.
4.1 Definition of MEAs
The understanding of what constitutes an MEA may differ
across countries. For example, although its legislation does
not officially permit MEAs, Slovakia implements some
confidential discounts that would fit under the MEA defi-
nition used in this study. Some countries implement
informal MEAs (in the sense that they do not classify them
as MEAs). These include free doses, which have some-
times been used before formal MEA arrangements were
put in place (e.g. Romania), as well as unofficial discounts
in Slovakia. Coverage with evidence development (condi-
tional/temporary reimbursement) in the Czech Republic
and Slovakia is also functionally similar to MEAs,
although in both countries it is determined by specific
conditions defined by law, rather than contractually.
However, the recent addition of MEAs to new temporarily
reimbursed medicines in the case of the Czech Republic
suggests that coverage with evidence development alone
was not sufficient to mitigate the long-term financial risk
for payers.
Differences in what is considered to be an MEA in one
country versus what is considered to be an MEA in another
country raises the question as to where the boundaries
between MEAs and non-MEAs lie. In the end, what con-
stitutes an MEA is a matter of definition. Consequently,
when comparing MEA implementation across countries, it
is therefore important to be aware that the understanding of
what is classified as an MEA can differ between countries.
4.2 Administrative Burden
We found only a very small number of health outcome-
based agreements involving monitoring of clinical out-
comes in our study. This is likely to be in recognition that
these agreements are resource intensive to implement and
require good IT systems with electronic clinical records
linked to reimbursement systems to be successfully
enacted.
In most countries included in this study, the financial
agreements in place need to be renegotiated on a regular
basis (usually every 1–5 years). Depending on the effort
required for their renegotiation, this can add administrative
burden to MEA implementation, which needs to be con-
sidered when designing and implementing MEAs. For this
reason, where MEAs cover a number of medicines, and
where their duration is limited and their implementation is
a precondition for reimbursement, authorities should con-
sider whether the time invested in negotiation is not
excessive and whether alternative options may prove less
burdensome to administrate (e.g. negotiate the agreements
for a longer period of time).
Beyond the frequency of re-negotiation, the type of
agreement and the way it is implemented can have an
important impact on the administration of the agreement.
For example, payback agreements may involve a refund on
overspending or the provision of free stock after an agreed
threshold is reached. To keep the administrative burden to
a minimum, countries implementing agreements involving
refunds should consider whether obtaining the refund is
labour intensive and whether it is effective (i.e. are refunds
actually obtained and, if yes, are they obtained in a timely
fashion?). In the case of free stock, is free stock promptly
requested and provided after the agreed threshold is
reached? Discounts were the most common type of
agreement implemented in Slovenia, where only a limited
number of payback agreements were in place. In a country
such as Slovenia, where good treatment guidelines are in
place and implemented [36], it may be easier to agree on
the number of patients to be treated, along with a discount,
rather than having payback agreements involving refunds
in place.
4.3 Other Approaches to Improve Access
In Bosnia and Herzegovina, both The Federation of Bosnia
and Herzegovina and the Republic of Srpska, also have
special funds and budgets in place for the financing of
expensive medicines, which are innovative and under
patent. Similar earmarked funds are available in Scotland
(the New Medicines Fund funded by the Pharmaceutical
Price Regulation Scheme [PPRS] rebates) [35] and Eng-
land (the Cancer Drugs Fund) [36]. However, support for
such earmarked funds is mixed. While they facilitate
access, critics raised issues about fairness towards other
disease areas and patient groups that are not eligible for
special funding [3, 39]. Further, the views of a Patient and
Clinician Engagement meeting in Scotland [37] and the
end-of-life criteria in England [38] offer opportunities for
special considerations affecting medicines for end-of-life
and very rare conditions to be taken into account in the
health technology assessment process.
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Named-patient programmes, similar to the individual
patient requests in the UK, have been implemented in the
Czech Republic, Hungary, Poland, and Slovakia, but under
different names. In Slovakia, for example, €32 million has
been allocated for a population of 5.4 million inhabitants,
totalling 4% of the pharmaceutical budget [40, 41]. In
Hungary, €26 million was allocated for 2016 and
€72 million was actually spent for a 9.9 million popula-
tion. Overspending was due to delayed listing decisions for
high-budget-impact medicines for the treatment of mela-
noma, prostate cancer and myeloma multiplex, among
other therapeutic areas. Spending on exceptional reim-
bursement has also been increasing in the Czech Republic,
where the largest health insurance fund alone spent
€28.6 million in 2015, an almost threefold increase since
2013. New expensive medicines, which face the risk of
being rejected on cost-effectiveness grounds, have been
made available to some Slovak patients directly through
the ‘system of exceptions’, without applying for regular
reimbursement.
4.4 Definition of ‘Risk’, ‘Risk Sharing’ and High
Prices
Considering how the agreements are implemented in
European countries, risk seems to be implicitly defined as
risk of excessive spending and/or spending on non-cost-
effective medicines and/or use in patient groups for whom
the medicine was not intended (quality use of medicines).
What is defined as ‘risk sharing’ probably depends on what
is considered to be ‘fair sharing’ between the payer and the
manufacturer. In countries with hard incremental cost-ef-
fective ratio (ICER) thresholds, a fair level of ‘risk sharing’
could be defined as an agreement that reduces the actual
price paid by the payer to a level that brings the medicine
within the willingness-to-pay threshold of that country. We
did not find any specific country definitions of what con-
stituted ‘risk’ and ‘risk-sharing’, mainly because these
agreements were not called risk-sharing agreements in
national policy documents. The term ‘risk’ seems to have
been used more in the literature [8, 12, 15, 42–48], par-
ticularly the theoretical literature, than in national policy
documents, which could explain why the countries inclu-
ded in our study have not developed definitions for it.
Similarly, although the terms ‘high cost’ or ‘high priced’
are widely used in the literature and in policy discussion,
there is no standardised definition of which medicines are
classified as such. Again, implicitly, these medicines are
broadly understood as being new medicines (i.e. still under
patent), especially new biological medicines and targeted
therapies, for the treatment of cancer, conditions affecting
the immune system (e.g. rheumatoid arthritis), infectious
diseases (hepatitis C), and rare conditions. For example, in
the Federation of Bosnia and Herzegovina, a list of
expensive medicines eligible for funding through the Sol-
idarity Fund is publicly available. While there is no defi-
nition of what an expensive medicine is, the list includes,
not surprisingly, oncology, biological therapies and HIV
medicines.
4.5 Limitations
Due to the confidentiality surrounding the agreements in
place, only some of the countries were able to report
quantitative informative on the type of agreements imple-
mented and their therapeutic group.
5 Conclusions
We believe this is the first comprehensive comparative
study on the implementation of MEAs in CEE involving
key decision makers, their advisers and other senior per-
sonnel within these countries. While the information
available on MEAs varied across countries, some prelim-
inary conclusions and recommendations can be made.
Experience in implementing MEAs varied substantially
across the region and there is considerable scope for
sharing experiences and mutual learning. To increase
transparency, non-commercially sensitive information on
the implementation of MEAs (type, therapeutic group)
should be made publicly available. European citizens,
authorities and the industry should ask themselves whether,
within publicly funded health systems, confidential dis-
counts can still be tolerated. This is all the more important
given the lack of clarity as to which country and party are
really benefiting from MEAs. Industry supports their
implementation as a way to discriminate prices - and
improve access in less resourced countries - in a system of
international price referencing. The question is whether
industry is best placed to ensure equity in access and
whether it would offer larger discounts to countries that can
least afford the new medicine and most need them. The
lack of transparency is being allowed by the European
Commission, but individual countries are finding price
confidentiality increasingly unacceptable. This needs to be
addressed.
The impact of MEAs on access to medicines should be
monitored and evaluated. While a number of countries
implement MEAs, strong budgetary pressures still apply,
which limit the number of patients that can be treated with
new expensive medicines, even in countries implementing
MEAs. If MEAs are to improve access to medicines that
bring meaningful added clinical value and are cost effec-
tive, countries should establish clear objectives for their
implementation and a monitoring framework to measure
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their performance as well as the burden of implementation.
In addition, they should look closely at issues of afford-
ability among patients if this is a concern.
Overall, it appears unlikely that MEAs represent a sus-
tainable solution to improving access to effective medici-
nes that bring a meaningful added value to patients. If this
was the case, countries implementing MEAs would not be
struggling in balancing access and financial sustainability.
In reality, MEAs seem to be a model that has been offered
by the pharmaceutical industry and accepted by countries
in the absence of a better alternative, which both parties are
willing to implement. New models of financing research
and development, and manufacturing and distributing
medicines that address current unmet medical needs, are
required to ensure sustainable and equitable access to new
medicines.
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